Theory and applications of differential scanning fluorimetry in early-stage drug discovery

被引:156
|
作者
Gao K. [1 ]
Oerlemans R. [1 ]
Groves M.R. [1 ]
机构
[1] Structure Biology in Drug Design, Drug Design Group XB20, Departments of Pharmacy, University of Groningen, Groningen
关键词
Buffer optimization; Crystallization; Fluorimetry; Folding; Ligands screening; Refolding; Thermal stability; Unfolding;
D O I
10.1007/s12551-020-00619-2
中图分类号
学科分类号
摘要
Differential scanning fluorimetry (DSF) is an accessible, rapid, and economical biophysical technique that has seen many applications over the years, ranging from protein folding state detection to the identification of ligands that bind to the target protein. In this review, we discuss the theory, applications, and limitations of DSF, including the latest applications of DSF by ourselves and other researchers. We show that DSF is a powerful high-throughput tool in early drug discovery efforts. We place DSF in the context of other biophysical methods frequently used in drug discovery and highlight their benefits and downsides. We illustrate the uses of DSF in protein buffer optimization for stability, refolding, and crystallization purposes and provide several examples of each. We also show the use of DSF in a more downstream application, where it is used as an in vivo validation tool of ligand-target interaction in cell assays. Although DSF is a potent tool in buffer optimization and large chemical library screens when it comes to ligand-binding validation and optimization, orthogonal techniques are recommended as DSF is prone to false positives and negatives. © 2020, The Author(s).
引用
收藏
页码:85 / 104
页数:19
相关论文
共 50 条
  • [1] The future for early-stage tuberculosis drug discovery
    Zuniga, Edison S.
    Early, Julie
    Parish, Tanya
    FUTURE MICROBIOLOGY, 2015, 10 (02) : 217 - 229
  • [2] Exploiting genomics and proteomics for rapid, early-stage drug discovery
    Bailey, DS
    BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135
  • [3] Overview of computational methods employed in early-stage drug discovery
    Skjevik, Age Aleksander
    Teigen, Knut
    Martinez, Aurora
    FUTURE MEDICINAL CHEMISTRY, 2009, 1 (01) : 49 - 63
  • [4] Bayes optimal informer sets for early-stage drug discovery
    Yu, Peng
    Ericksen, Spencer
    Gitter, Anthony
    Newton, Michael A.
    BIOMETRICS, 2023, 79 (02) : 642 - 654
  • [5] Developing and applying computational approaches in early-stage drug discovery
    Balius, Trent
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [6] Deployment of in silico and in vitro safety assays in early-stage drug discovery
    Will, Yvonne
    Schroeter, Thomas
    FUTURE MEDICINAL CHEMISTRY, 2012, 4 (10) : 1211 - 1213
  • [7] Transforming the work of early-stage drug discovery through bioprocess informatics
    Holzman, TF
    Hebert, EJ
    DRUG DISCOVERY TODAY, 2005, 10 (01) : 61 - 67
  • [8] Managing the health of early-stage discovery
    Michael Edwards
    Tony Tramontin
    Daniel Simon
    Ajay Dhankhar
    Mubasher Sheikh
    Nature Reviews Drug Discovery, 2011, 10 : 171 - 172
  • [9] Label-Free Characterization of a Novel Early-Stage Drug Discovery Platform
    Esposito, Edward
    Frasca, Verna
    Mattison, Kevin
    BIOPHYSICAL JOURNAL, 2015, 108 (02) : 258A - 259A
  • [10] Editorial for Special Issue-"Early-Stage Drug Discovery: Advances and Challenges"
    Sippl, Wolfgang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)